MediciNova (NASDAQ:MNOV – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.
Institutional & Insider Ownership
9.9% of MediciNova shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares MediciNova and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $410,000.00 | 206.48 | -$12.00 million | ($0.21) | -8.19 |
| Unicycive Therapeutics | $680,000.00 | 188.44 | -$26.56 million | ($1.75) | -2.63 |
MediciNova has higher earnings, but lower revenue than Unicycive Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for MediciNova and Unicycive Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
MediciNova currently has a consensus price target of $7.75, indicating a potential upside of 350.58%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 296.65%. Given MediciNova’s stronger consensus rating and higher possible upside, equities analysts clearly believe MediciNova is more favorable than Unicycive Therapeutics.
Summary
MediciNova beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
